Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Nishant Shah

Preventive Cardiology · Duke Hospital

View

Dr. Amit Khera

Preventive Cardiology · UT Southwestern

View

Dr. Martha Gulati

Preventive Cardiology · Houston Methodist

View

Dr. Pradeep Natarajan

Preventive Cardiology · MGH

View

Dr. Christopher Cannon

Preventive Cardiology · BWH

View

Dr. Nicholas Marston

Preventive Cardiology · BWH

View

Dr. Dorairaj Prabhakaran

General Cardiology

View

Dr. Pugazhendhi Vijayaraman

EP · Geisinger

View

Dr. Robert Schaller

EP · HUP

View

Dr. Trey Woods

General Cardiology · Emory Healthcare

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    LLDr. Luke Laffin

    Dr. Luke Laffin

    Cardiology · Preventive Cardiology
    Cleveland Clinic
    luke

    Research

    Aldosterone synthase inhibitors for hypertension: A breakthrough facing barriers to adoption

    2026

    Via PLOS Medicine

    Research

    Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design

    2026

    Via JACC Advances

    Research

    Addressing Hypertension Treatment Disparities Via Renal Denervation.

    2026

    Via Current Hypertension Reports

    Research

    Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial.

    2026

    Via JAMA Internal Medicine

    Research

    Inaccurate information regarding cardiovascular disease prevention enabled by generative artificial intelligence.

    2026

    Via American Journal of Preventive Cardiology

    Research

    Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists.

    2026

    Via Reviews in Cardiovascular Medicine

    Research

    An expert opinion on heart failure in hypertensive heart disease.

    2026

    Via European Journal of Heart Failure

    Research

    In vivo gene editing for lipid management: An early perspective from ANGPTL3-targeted CRISPR-Cas9 therapy.

    2026

    Via Molecular Therapy

    Research

    Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design.

    2026

    Via JACC Advances

    Research

    Aldosterone synthase inhibitors for hypertension: A breakthrough facing barriers to adoption.

    2026

    Via PLoS Medicine

    Mar 19, 2026Journal Article

    Angiotensinogen Reconsidered: Evolving Perspectives in Hypertension Research.

    ​

    Written by 1 Roon author & 4 others

    Via The American Heart Association Journals

    Research

    Endothelial triple-pathway vasorelaxation as an adjunctive strategy in resistant hypertension.

    2026

    Via Journal of Hypertension

    Research

    Aldosterone synthase inhibition in hypertension: an evolving therapeutic strategy.

    2026

    Via Current Opinion in Cardiology

    Research

    Aldosterone synthase inhibitors for hypertension: A breakthrough facing barriers to adoption

    2026

    Via PloS Medicine

    Research

    Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design

    2026

    Via JACC. Advances